Number of shares and votes in Calliditas Therapeutics
Calliditas Therapeutics AB announced the issuance of 706,676 common shares related to the over-allotment option from its IPO on July 31, 2020. Additionally, 1,185,250 common shares were issued from the conversion of warrants from a 2017 program. The total number of shares and votes in the company now stands at 49,830,334. Calliditas continues to focus on developing treatments for unmet medical needs, especially in renal and hepatic diseases, with its lead product candidate, Nefecon, targeting IgA nephropathy.
- Increased share count to 49,830,334 enhances liquidity.
- Successful execution of over-allotment option indicates strong investor interest.
- Dilution of existing shares due to new issuances may negatively impact shareholder value.
STOCKHOLM, July 31, 2020 /PRNewswire/ -- During July, Calliditas Therapeutics AB (publ) has issued 706,676 common shares as a result of the exercise of the over-allotment option within the initial public offering on The Nasdaq Global Select Market and the concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States. Further, during July, warrants within the company's warrant program issued in 2017 have been converted to 1,185,250 common shares. Thus, as of July 31, 2020, the number of shares and votes in the company amounts to 49,830,334.
For further information, please contact:
Renée Aguiar-Lucander, CEO at Calliditas
Tel.: +46-722-52-10-06, email: renee.lucander@calliditas.com
Mikael Widell, Head of Communications and IR
Tel.: +46-703-11-99-60, email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 12:00 pm CEST on July 31, 2020.
About Calliditas
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301103784.html
SOURCE Calliditas Therapeutics
FAQ
What is the latest share count for Calliditas Therapeutics as of July 31, 2020?
How many shares were issued from the over-allotment option in July 2020?
What is the significance of the warrants conversion mentioned in the press release?
How does this press release impact shareholders of CALT?
What is Calliditas Therapeutics' focus area as per the press release?
